Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian Melanoma Testing Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedPresbyterian Health PlanPolicy 7.7

    Genetic Testing for Cutaneous Melanoma

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 7.7 alerts

    Get alerted when Policy 7.7 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for molecular and gene-expression tests used to diagnose, characterize, or risk-stratify cutaneous melanoma. Coverage differs by product line, with Medicare and Medicaid coverage following applicable WPS or MolDX guidance and commercial testing generally considered experimental, investigational, or unproven.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing for Cutaneous Melanoma
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateAug 27, 2025
    Key ActionSubmit prior authorization through Pres Online for all four tests when requested for Medicare or Medicaid members.
    SourceLink
    POLICY UPDATE CHANGES

    As of the 08-27-2025 annual review, Medicare and Medicaid coverage continued for myPath Melanoma (0090U), DecisionDx DiffDx Melanoma (0314U), Pigmented Lesion Assay by DermTech (0089U), and DecisionDx Melanoma (81529).

    DecisionDx Melanoma (81529) was moved from the exclusion section to covered status for Medicare and Medicaid, and its investigational and experimental configuration was removed for those lines of business.

    Prior authorization is required for all four gene expression profiling tests for Medicare and Medicaid.

    All four tests are non-covered for the Commercial line of business because leading oncology guidance considers the gene expression profiling tests investigational, experimental, or of uncertain clinical utility.

    Pigmented Lesion Assay (0089U) was removed from the investigative policy and added to the applicable investigative and new technology policy for Medicare and Medicaid coverage.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Required
    Prior authorization
    4Tests addressed
    Medicare/MedicaidPublic-program coverage
    Non-coveredCommercial coverage
    08-27-2025Annual review

    Test-Specific Coverage Criteria

    Medicare and Medicaid Covered Tests

    Covered for Medicare and Medicaid when applicable LCD/LCA requirements are met and prior authorization is obtained.

    ALL of the following

    • myPath Melanoma (CPT 0090U) is used as a diagnostic test for neoplasm of uncertain behavior of the lip or skin, consistent with WPS Molecular Assays for the Diagnosis of Cutaneous Melanoma LCD L39479 and LCA A59261.
    • The applicable Medicare or Medicaid coverage requirements are satisfied.
    • Prior authorization is obtained before testing.

    Medicare and Medicaid Covered Tests

    Covered for Medicare and Medicaid when applicable LCD/LCA requirements are met and prior authorization is obtained.

    ALL of the following

    • DecisionDx® DiffDx™ Melanoma (CPT 0314U) is used as a diagnostic test for neoplasm of uncertain behavior of the lip or skin, consistent with WPS Molecular Assays for the Diagnosis of Cutaneous Melanoma LCD L39479 and LCA A59261.
    • The applicable Medicare or Medicaid coverage requirements are satisfied.
    • Prior authorization is obtained before testing.

    Medicare and Medicaid Covered Tests

    Covered for Medicare and Medicaid when applicable LCD/LCA requirements are met and prior authorization is obtained.

    ALL of the following

    • Pigmented Lesion Assay (PLA) by DermTech (CPT 0089U) is used only on a pigmented skin lesion for which a diagnosis of melanoma is being considered, consistent with WPS Molecular Assays for the Diagnosis of Cutaneous Melanoma LCD L38178 and LCA A57983.
    • The applicable Medicare or Medicaid coverage requirements are satisfied.
    • Prior authorization is obtained before testing.

    Medicare and Medicaid Covered Tests

    Covered for Medicare and Medicaid when the applicable Medicare LCD/LCA requirements are met and prior authorization is obtained.

    ALL of the following

    • DecisionDx Melanoma (CPT 81529), a 31-gene expression tumor tissue profile test, is used to assist in melanoma risk stratification consistent with MolDX: Melanoma Risk Stratification Molecular Testing LCD L38018, related LCA A56636, or another applicable outside-region LCD issued by the member's A/B MAC.
    • The applicable Medicare or Medicaid coverage requirements are satisfied.
    • Prior authorization is obtained before testing.

    Medicare and Medicaid Covered Tests

    Medicare and Medicaid coverage applies to all four listed tests only when applicable coverage requirements are met.

    ALL of the following

    • The test is one of the covered GEP tests: myPath Melanoma (0090U), DecisionDx® DiffDx™ Melanoma (0314U), Pigmented Lesion Assay by DermTech (0089U), or DecisionDx Melanoma (81529).
    • Applicable Medicare or Medicaid LCD/LCA requirements are satisfied, including the relevant WPS, MolDX, or other applicable A/B MAC policy.
    • Prior authorization is obtained before testing.

    Commercial Non-Coverage

    Commercial coverage is not available for the listed tests.

    ALL of the following

    • The member is enrolled in the Commercial line of business.
    • The requested test is myPath Melanoma (0090U), DecisionDx® DiffDx™ Melanoma (0314U), Pigmented Lesion Assay by DermTech (0089U), or DecisionDx Melanoma (81529).
    • The test is considered experimental, investigational, or unproven under NCCN and/or MCG guidance and is therefore not covered.

    For Commercial members, gene-expression profiling and Pigmented Lesion Assay testing is addressed as non-covered because the testing is considered experimental, investigational, or unproven under NCCN and/or MCG guidance.

    Predictive gene-expression profiling tests intended to differentiate melanomas at low versus high risk for nodal metastasis should not replace discussion with surgical oncology regarding pathologic staging procedures. These tests are not recommended outside the context of a clinical study or trial.

    All four listed tests—myPath Melanoma (0090U), DecisionDx® DiffDx™ Melanoma (0314U), Pigmented Lesion Assay by DermTech (0089U), and DecisionDx Melanoma (81529)—are excluded from coverage for Commercial members.

    For Commercial members, gene-expression profiling tests are considered investigational, experimental, or unproven and remain non-covered. DecisionDx Melanoma (81529) is also configured as investigational for the applicable lines of business.

    Medicare and Medicaid Covered Indications

    Diagnostic Testing for Neoplasm of Uncertain Behavior of the Lip or Skin

    Covered for Medicare and Medicaid when all of the following apply:

    The test is myPath Melanoma or DecisionDx DiffDx Melanoma; it is used as a diagnostic test for neoplasm of uncertain behavior of the lip or skin; and coverage requirements under WPS Molecular Assays for the Diagnosis of Cutaneous Melanoma (L39479) and LCA A59261 are satisfied.

    Pigmented Lesion Assay for Suspected Melanoma

    Covered for Medicare and Medicaid when all of the following apply:

    The requested test is the Pigmented Lesion Assay; it is used on a pigmented skin lesion for which a diagnosis of melanoma is being considered; and coverage requirements under WPS Molecular Assays for the Diagnosis of Cutaneous Melanoma (L38178) and LCA A57983 are satisfied.

    DecisionDx-Melanoma Risk Stratification

    Covered for Medicare and Medicaid when all of the following apply:

    Clinical Eligibility Requirements

    The intended clinical context varies by test: myPath Melanoma and DecisionDx DiffDx Melanoma are used for diagnostic evaluation of a suspicious skin or cutaneous melanocytic lesion, including a lesion of uncertain malignant potential or an indeterminate biopsy; the Pigmented Lesion Assay is used for a pigmented skin lesion for which melanoma is being considered; and DecisionDx Melanoma is used for melanoma risk stratification.

    Non-Covered Services

    For Commercial members, gene-expression profiling and Pigmented Lesion Assay testing are not covered because the tests are considered experimental, investigational, or unproven under applicable oncology guidance.

    Applicable Laboratory Codes

    Covered CPT CodesCPTCovered
    81529Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis. e.g. DecisionDX Melanoma.
    Covered CPT CodesCPTCovered
    0089UOncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es) Pigmented Lesion Assay (DermTech Melanoma Test)
    Covered CPT CodesCPTCovered
    0090UOncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin- fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) myPath® Melanoma.
    Covered CPT CodesCPTCovered
    0314UOncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin- fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) DecisionDx® DiffDx ™ - Melanoma
    Genetic and molecular testing codesCPT
    81529Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis. e.g. DecisionDX Melanoma.
    0089UOncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es) Pigmented Lesion Assay (DermTech Melanoma Test)
    0090UOncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin- fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) myPath® Melanoma.
    0314UOncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin- fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) DecisionDx® DiffDx ™ - Melanoma

    Authorization, Documentation, and Submission Requirements

    Prior Authorization

    Submit prior authorization through Pres Online

    Prior authorization is required. Submit the request through Pres Online.

    Prior Authorization

    Obtain authorization for Medicare and Medicaid testing

    Prior authorization is required for all four tests for Medicare and Medicaid members.

    • DecisionDx Melanoma (81529)
    • myPath Melanoma (0090U)
    • DecisionDx DiffDx Melanoma (0314U)
    • Pigmented Lesion Assay by DermTech (0089U)

    Policy Background

    This policy addresses gene-expression and molecular assays used in the diagnosis and characterization of cutaneous melanoma and suspicious pigmented lesions, as well as in melanoma metastatic-risk stratification. The tests addressed include diagnostic profiling for lesions with uncertain malignant potential, noninvasive adhesive-patch testing for lesions in which melanoma is being considered, and gene-expression profiling used to assess melanoma recurrence or metastatic risk.

    Test and Method Definitions

    DecisionDx-Melanoma
    Test typeA 31-gene expression profile for cutaneous melanoma
    Five-year metastasis riskClassifies tumors as low risk (Class 1) or high risk (Class 2) for developing metastasis within 5 years of diagnosis
    Additional clinical informationA Class 1 tumor profile is associated with a low likelihood of sentinel lymph node positivity
    MyPath Melanoma
    Test typeA gene expression profiling test for suspicious skin or cutaneous melanocytic lesions
    Intended clinical useUsed when the lesion's malignant potential is uncertain
    Biopsy context
    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing for Cutaneous Melanoma
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateAug 27, 2025
    Key ActionSubmit prior authorization through Pres Online for all four tests when requested for Medicare or Medicaid members.
    SourceLink
    On This Page
    Test-Specific Coverage CriteriaMedicare and Medicaid Covered IndicationsClinical Eligibility RequirementsNon-Covered ServicesApplicable Laboratory CodesAuthorization, Documentation, and Submission RequirementsPolicy BackgroundTest and Method Definitions
    The requested test is DecisionDx-Melanoma and it is used for melanoma risk stratification consistent with MolDX Melanoma Risk Stratification Molecular Testing (L38018), related LCA A56636, or another applicable outside-region LCD issued by the A/B MAC that enrolled the provider and processes Medicare claims for the service.

    Gene-Expression Profiling Assays for Cutaneous Melanoma

    Covered for Medicare and Medicaid when all of the following apply:

    ALL of the following

    • One of four assays: DecisionDx Melanoma (81529), myPath Melanoma (0090U), DecisionDx DiffDx Melanoma (0314U), or Pigmented Lesion Assay by DermTech (0089U).One of four tests
    • Applicable coverage requirements: The applicable Medicare LCD/LCA criteria are met and prior authorization is obtained.Both required
    Documentation Required

    Maintain supporting clinical documentation

    Maintain or have access to appropriate documentation supporting coverage when Presbyterian follows LCDs, LCAs, NCCN, MCG, or other cited guidelines. The documentation may be requested during coverage review.

    Documentation Required

    Provide additional medical necessity information

    For cases that do not meet the stated guidelines, submit additional information supporting medical necessity for medical director review.

    Denial Risk

    Commercial GEP and PLA testing is not covered

    For Commercial members, testing with gene-expression profiling or the Pigmented Lesion Assay is considered experimental, investigational, or unproven and is not covered.

    Denial Risk

    Do not substitute predictive GEP for surgical staging

    Predictive gene-expression profiling intended to differentiate melanomas at low versus high risk for nodal metastasis should not replace surgical oncology discussion of pathologic staging procedures. It is not recommended outside the context of a clinical study or trial.

    Note

    Verify member benefit applicability

    Verify coverage against the member's specific benefit plan and Schedule of Benefits. The service may not be a benefit on all plans, or the plan may provide broader or more limited benefits than those listed in this policy.

    Denial Risk

    Commercial requests are non-covered

    Commercial requests for any of the four gene-expression profiling tests are non-covered because NCCN and other cited oncology sources consider the tests investigational, experimental, or of uncertain clinical utility.

    • DecisionDx Melanoma (81529)
    • myPath Melanoma (0090U)
    • DecisionDx DiffDx Melanoma (0314U)
    • Pigmented Lesion Assay (0089U)
    Denial Risk

    Meet applicable LCD/LCA requirements

    Medicare and Medicaid requests may be denied when the applicable LCD or LCA criteria are not met or when required supporting documentation is not available.

    Intended when the initial biopsy is indeterminate for melanoma
    Pigmented Lesion Assay (PLA)
    Test typeA proprietary, noninvasive adhesive patch biopsy genetic test
    Target lesionsPigmented melanocytic skin lesions for which melanoma is being considered
    Clinical useHelps dermatologists rule out melanoma and the need for surgical biopsy of atypical pigmented lesions
    Gene Expression Profiling
    MethodGene expression profiling by real-time or quantitative reverse-transcription polymerase chain reaction
    Gene compositionUses a defined set of content genes and housekeeping genes
    Reported resultAn algorithm-generated diagnostic or recurrence-risk result
    Pigmented Lesion Assay
    Collection methodSuperficial collection using adhesive patch(es)
    Molecular targetsProfiles PRAME and LINC00518
    AssayPigmented Lesion Assay (DermTech Melanoma Test)